MEDIUM confidence: 100% data completeness, but the composite (53) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Avg target $104 (last qtr, 9 analysts) → $106 (last mo, 8) (+1.1%).
Buy-rated share 30% → 33% over ~3 months (+4pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $2.01 | $2.07 | +3.0% |
| Apr 2026 | $1.86 | $2.09 | +12.4% |
| Feb 2026 | $2.38 | $2.42 | +1.7% |
| Nov 2025 | $1.87 | $1.90 | +1.6% |
| Aug 2025 | $1.98 | $2.07 | +4.5% |
| May 2025 | $1.77 | $1.81 | +2.3% |
| Feb 2025 | $2.30 | $2.31 | +0.4% |
| Oct 2024 | $1.74 | $1.74 | +0.0% |
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $6.8B— | $6.9B+1.6% | $7.4B+6.5% | $7.7B+3.8% | $8.2B+7.2% |
| EPS (dil.) | $1.91— | $1.10-42.4% | $4.88+343.6% | $4.43-9.2% | $3.55-19.9% |
| Free Cash Flow | $1.3B— | $1.1B-20.8% | $1.2B+11.2% | $1.1B-3.7% | $1.5B+28.9% |
| Gross Margin | 71.3% | 70.9%-0.4pp | 71.8%+0.9pp | 71.5%-0.4pp | 61.6%-9.8pp |
| Operating Margin | 12.6% | 10.0%-2.6pp | 17.3%+7.2pp | 16.7%-0.5pp | 16.5%-0.2pp |
| Net Margin | 5.9% | 3.3%-2.5pp | 13.8%+10.5pp | 11.8%-2.1pp | 8.6%-3.2pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth below the analyst consensus of 4.2%/yr (revenue basis).
Base free cash flow $1.3B (avg FY2023–FY2025; latest year $1.5B) · equity value $19.1B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
Net insider -$664K over 180 days (0 open-market buys, 3 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
The QScore of 53 for Zimmer Biomet Holdings indicates a neutral outlook, driven by a mix of factors. The stock scores high on profitability, with a strong gross margin of 69.9%, and exhibits low risk, with a beta of 0.5. However, its growth score is dragged down by a decline in EPS growth of -20.0%, while its momentum is marked by a recent surge, with a 3-month return of 19.6%, but a 12-month return of -2.8%. The long-term and short-term scores are relatively aligned, suggesting a consistent view of the stock's prospects.